Can flecainide cause renal impairment?

Flecainide and Renal Impairment

Flecainide does not directly cause intrinsic renal damage, but renal impairment significantly affects flecainide elimination and increases toxicity risk, requiring mandatory dose reduction in patients with creatinine clearance <35-50 mL/min. 1, 2

Renal Elimination and Dose Adjustment Requirements

The critical relationship between flecainide and the kidneys is pharmacokinetic, not nephrotoxic:

• Approximately 30% (range 10-50%) of flecainide is excreted unchanged in urine, making renal function a major determinant of drug clearance 2
• With increasing renal impairment, unchanged drug excretion decreases and plasma half-life becomes significantly prolonged 2
• In severe renal impairment (creatinine clearance ≤35 mL/min), the initial dose must be reduced to 100 mg once daily, with frequent plasma level monitoring required 1, 3, 2
• For moderate renal dysfunction (creatinine clearance 35-50 mL/min), flecainide is contraindicated according to ESC guidelines unless carefully dose-adjusted 1
• Plasma level monitoring is mandatory in renal impairment because there is no simple linear relationship between creatinine clearance and flecainide elimination rate 2

Rare Case Reports of Acute Interstitial Nephritis

While flecainide does not typically cause kidney damage, isolated case reports document acute interstitial nephritis (AIN):

• One case described biopsy-proven AIN in a pregnant patient receiving flecainide 200 mg/day for 10 days, with concurrent NSAID exposure (ibuprofen and diclofenac) 4
• The patient's creatinine rose from 30 μmol/L to 411 μmol/L within 7 days post-cesarean section, with renal biopsy confirming AIN 4
• This suggests flecainide may cause AIN, particularly when combined with NSAIDs, though this remains extremely rare 4

Dangerous Drug Interactions in Renal Dysfunction

The combination of flecainide with drugs affecting renal hemodynamics creates life-threatening toxicity risk:

• Combining flecainide with ACE inhibitors, diuretics, and NSAIDs can precipitate acute renal failure and flecainide overdose 5
• NSAIDs modify glomerular hemodynamics and can rapidly worsen renal function in patients on flecainide, leading to toxic drug accumulation 5
• Avoid NSAIDs in patients taking flecainide, especially those with any degree of renal impairment 4, 5

Clinical Manifestations of Flecainide Toxicity in Renal Failure

Renal impairment-induced flecainide toxicity presents with severe cardiac and neurologic manifestations:

• Wide-complex tachycardia or bradycardia, loss of pacemaker capture, and cardiac arrest have been reported 6, 7
• Neurologic symptoms include altered mental status, visual hallucinations, and encephalopathy 8
• Flecainide toxicity can develop even after drug discontinuation and dialysis due to large volume of distribution and lipophilicity 6
• Hemodialysis removes only about 1% of an oral flecainide dose, making it ineffective for toxicity management 2

Monitoring Requirements in Renal Impairment

Patients with any degree of renal dysfunction require intensive monitoring:

• Obtain baseline renal function (creatinine clearance) before initiating flecainide 1, 3, 2
• Monitor renal function regularly during therapy to guide dose adjustments 3, 9, 2
• Measure trough plasma flecainide levels (target 0.2-1.0 mcg/mL; levels >1.0 mcg/mL increase cardiac adverse event risk) 2
• Perform ECG monitoring for QRS widening >25% from baseline, which signals heightened proarrhythmic risk 3, 9
• In severe renal impairment, dosage increases should be made very cautiously only after plasma levels plateau (>4 days), as steady-state may take longer to achieve 2

Common Pitfall to Avoid

The most critical error is failing to recognize that flecainide is contraindicated in moderate-to-severe renal impairment without appropriate dose reduction. Prescribers must calculate creatinine clearance before initiating therapy and adjust dosing accordingly, as standard doses will lead to toxic accumulation 1, 3, 2. Additionally, avoid combining flecainide with NSAIDs in any patient, but especially those with compromised renal function 4, 5.